Clinical Trial

177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 10, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-PSMA-EB-01, a new PSMA-specific radiopharmaceutical, in patients with metastatic castration resistant prostate cancer (mCRPC) who will undergo radioligand therapy (RLT). All patients underwent 68Ga-PSMA and 18F-FDG PET/CT for selection and were randomly divided into three groups of 3 people each.The three groups received an approximately 1.11 GBq (30mCi), 1.85 GBq (50 mCi) and 2.59 GBq (70mCi) of 177Lu-PSMA-EB-01 up to 2 cycles, respectively.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05613738
Lead Sponsor Peking Union Medical College Hospital
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 9 participants
Start Date 2022-11-23
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-11-15 (estimated)
Updated on ClinicalTrials.gov 2024-07-10